CEO SUMMARY: As the closing year of the first decade of the new century and the new millennium, 2009 brought neither disruption nor upheaval to the majority of laboratories in the United States. Rather, it was marked by at least two themes. One was how public disclosure of problems with lab testing services generated media
Tag: clinical molecular diagnostics
GE Healthcare’s digital pathology joint venture with the University of Pittsburgh Medical Center (UPMC), announced on June 5, is not the only in vitro diagnostics (IVD) investment by GE during 2008. Just this May, GE paid $738 million to acquire Whatman, PLC, of Kent, England. With annual sales of $230 million, Whatman offers products described
HERE ARE THE TOP TEN MOLECULAR DIAGNOSTICS COMPANIES, ranked by revenues from international sales of clinical molecular products during 2004.
Collectively, these ten firms generated total revenues of $1.74 billion. By itself, Roche Diagnostics represents 40% of this market. One reason for this large number is the revenues generated by the PCR patents the company owns.
CEO SUMMARY: It was about 15 years ago when William Beaumont Hospital and Beaumont Reference Laboratories first began offering molecular diagnostic testing services to clinicians. This successful effort came about because of effective strategic planning, use of consulting expertise at key junctures, and careful evaluation of the finances for each molecular assay added to the
CEO SUMMARY: Presented here are THE DARK REPORT’S “Ten Biggest Lab Stories of 2004.” These are the events we consider most important to the lab industry during the year. However, in contrast to past years, 2004 lacked the types of blockbuster events which radically change and reshape the competitive landscape. Instead, 2004 was a relatively